ArticleOncology reports2024

Targeting adenocarcinoma and enzalutamide‑resistant prostate cancer using the novel anti‑androgen inhibitor ADA‑308.

Shaghayegh Nouruzi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.